CIK 0001840233 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Xilio Therapeutics, Inc.
Sign in to watch- Ticker
- XLO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 851623397
- Phone
- 617-833-1027
- Business address
- 828 WINTER STREET, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 8 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-16 | Shannon James Samuel Director | Purchase | +45,000 | $0.69 | $31K | 45,000 |
| 2025-06-16 | Russo Rene PRESIDENT AND CEO | Purchase | +36,289 | $0.68 | $25K | 281,172 |
| 2025-06-11 | ROSS ROBERT W. Director | Grant or award · Stock Option (right to buy) | +31,000 | 31,000 | ||
| 2025-06-11 | Brennan Aoife Director | Grant or award · Stock Option (right to buy) | +31,000 | 31,000 | ||
| 2025-06-11 | Bonstein Sara Director | Grant or award · Stock Option (right to buy) | +31,000 | 31,000 | ||
| 2025-06-11 | Curran Daniel J. Director | Grant or award · Stock Option (right to buy) | +31,000 | 31,000 | ||
| 2025-06-11 | Clancy Paul J Director | Grant or award · Stock Option (right to buy) | +31,000 | 31,000 | ||
| 2025-06-11 | Xu Yuan Director | Grant or award · Stock Option (right to buy) | +31,000 | 31,000 | ||
| 2025-06-11 | Shannon James Samuel Director | Grant or award · Stock Option (right to buy) | +31,000 | 31,000 | ||
| 2025-06-11 | Rossi Christina Director | Grant or award · Stock Option (right to buy) | +31,000 | 31,000 | ||
| 2025-06-10 | Bello Akintunde Olatokumbo Director | Grant or award · Stock Option (right to buy) | +62,000 | 62,000 | ||
| 2025-06-05 | GILEAD SCIENCES, INC. 10% owner | Purchase · Prefunded Warrants (right to buy) | +13,335,000 | 23,310,266 | ||
| 2025-06-05 | GILEAD SCIENCES, INC. 10% owner | Purchase · Series A Warrants (right to buy) | +13,335,000 | 13,335,000 | ||
| 2025-06-05 | GILEAD SCIENCES, INC. 10% owner | Purchase · Series B Warrants (right to buy) | +13,335,000 | 13,335,000 | ||
| 2025-06-05 | GILEAD SCIENCES, INC. 10% owner | Purchase · Series C Warrants (right to buy) | +13,335,000 | 13,335,000 | ||
| 2025-04-15 | Russo Rene PRESIDENT AND CEO | Grant or award · Stock Option (right to buy) | +190,000 | 190,000 | ||
| 2025-04-15 | Frankenfield Christopher James Chief Financial Officer | Grant or award · Stock Option (right to buy) | +75,000 | 75,000 | ||
| 2025-01-02 | Frankenfield Christopher James Chief Financial Officer | Sale 10b5-1 | −6,954 | $0.98 | $7K | 12,421 |
| 2025-01-02 | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | Sale 10b5-1 | −1,803 | $0.98 | $2K | 3,197 |
| 2025-01-01 | Frankenfield Christopher James Chief Financial Officer | Option exercise 10b5-1 | +19,375 | 19,375 |
Page 5 of 12 · 224 trades